%0 Journal Article %1 Klamt.1998b %A Klamt, B. %A Schulze, M. %A Thaete, C. %A Mares, J. %A Goetz, P. %A Kodet, R. %A Scheulen, W. %A Weirich, A. %A Graf, N. %A Gessler, M. %D 1998 %J Genes Chromosomes Cancer %K 11/drug 16/drug 22/drug Agents/therapeutic Alleles Antineoplastic Chromosomes;Human/drug Chromosomes;Human;Pair Chromosomes;Pair Drug Heterozygosity/drug Humans Loss Resistance;Neoplasm/genetics Tumor/drug Wilms effects/*genetics effects/genetics of therapy/*genetics/*pathology use %N 4 %P 287--294 %T Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters %V 22 %X An extended analysis for loss of heterozygosity (LOH) on eight chromosomes was conducted in a series of 82 Wilms tumors. Observed rates of allele loss were: 9.5\% (1p), 5\% (4q), 6\% (6p), 3\% (7p), 9.8\% (11q), 28\% (11p15), 13.4\% (16q), 8.8\% (18p), and 13.8\% (22q). Known regions of frequent allele loss on chromosome arms 1p, 11p15, and 16q were analyzed with a series of markers, but their size could not be narrowed down to smaller intervals, making any positional cloning effort difficult. In contrast to most previous studies, several tumors exhibited allele loss for multiple chromosomes, suggesting an important role for genome instability in a subset of tumors. Comparison with clinical data revealed a possible prognostic significance, especially for LOH on chromosome arms 11q and 22q with high frequencies of anaplastic tumors, tumor recurrence, and fatal outcome. Similarly, LOH 16q was associated with anaplastic and recurrent tumors. These markers may be helpful in the future for selecting high-risk tumors for modified therapeutic regimens.

@article{Klamt.1998b, abstract = {An extended analysis for loss of heterozygosity (LOH) on eight chromosomes was conducted in a series of 82 Wilms tumors. Observed rates of allele loss were: 9.5{\%} (1p), 5{\%} (4q), 6{\%} (6p), 3{\%} (7p), 9.8{\%} (11q), 28{\%} (11p15), 13.4{\%} (16q), 8.8{\%} (18p), and 13.8{\%} (22q). Known regions of frequent allele loss on chromosome arms 1p, 11p15, and 16q were analyzed with a series of markers, but their size could not be narrowed down to smaller intervals, making any positional cloning effort difficult. In contrast to most previous studies, several tumors exhibited allele loss for multiple chromosomes, suggesting an important role for genome instability in a subset of tumors. Comparison with clinical data revealed a possible prognostic significance, especially for LOH on chromosome arms 11q and 22q with high frequencies of anaplastic tumors, tumor recurrence, and fatal outcome. Similarly, LOH 16q was associated with anaplastic and recurrent tumors. These markers may be helpful in the future for selecting high-risk tumors for modified therapeutic regimens.}, added-at = {2013-01-29T13:47:26.000+0100}, author = {Klamt, B. and Schulze, M. and Thaete, C. and Mares, J. and Goetz, P. and Kodet, R. and Scheulen, W. and Weirich, A. and Graf, N. and Gessler, M.}, biburl = {https://www.bibsonomy.org/bibtex/2a403996bc1807c87fb76006ee2f4eb71/ebch}, interhash = {3387dc813a7f186b899769b16f24aecb}, intrahash = {a403996bc1807c87fb76006ee2f4eb71}, journal = {Genes Chromosomes Cancer}, keywords = {11/drug 16/drug 22/drug Agents/therapeutic Alleles Antineoplastic Chromosomes;Human/drug Chromosomes;Human;Pair Chromosomes;Pair Drug Heterozygosity/drug Humans Loss Resistance;Neoplasm/genetics Tumor/drug Wilms effects/*genetics effects/genetics of therapy/*genetics/*pathology use}, number = 4, pages = {287--294}, timestamp = {2013-01-29T13:47:41.000+0100}, title = {Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters}, volume = 22, year = 1998 }